Avanir Pharmaceuticals’ AVP 13358 for Asthma
May 3, 2004 by admin · Leave a Comment
On May 3, 2004 Avanir Pharmaceuticals released results of its Phase I clinical trial with AVP 13358 for asthma. The company reported that this trial, involving 54 healthy volunteers, was designed to demonstrate the safety, tolerability, and pharmacokinetic profile of a single oral administration of AVP 13358. The company indicated that AVP 13358 was well [...]
Iressa (Gefitinib) for Non Small Cell Lung Cancer
April 29, 2004 by admin · Leave a Comment
On April 29, 2004 The New England Journal of Medicine and Science magazine published early release articles online concerning Iressa. Both of these studies identified a sub-group of patients with non small cell lung cancer (NSCLC) and specific mutations in the EGFR gene. These articles concluded that screening for these mutations might identify patients who [...]
Zenapax (daclizumab)
March 19, 2004 by admin · Leave a Comment
On March 15, 2004 Protein Design Labs, Inc. reported results from the initial clinical study of the humanized antibody daclizumab in patients with chronic, persistent asthma whose disease was not well controlled with high doses of inhaled corticosteroid therapy. This Phase II randomized, double-blind, placebo-controlled clinical trial was conducted at 24 centers in the United [...]